Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 11/11/22 → 8/29/25 |
Funding
- Ellipses Pharma Limited: $68,301.00
22-MULTI-52-EP-PMC: A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies
- Arnold, Susanne (PI)